= 0.10 + 0.06 /M). The inhibition of 2-dGlc uptake is consistent with a decrease in the coupling between endofacial hexokinase activity and the sugar transporter. The evidence for this is:
INTRODUCTION
Glucocorticoids inhibit sugar transport in rat adipocytes (Carter-Su & Okamoto, 1985) , human erythocytes (Lacko et al., 1975) , chick-embryo fibroblasts (Rubin, 1977) , rat thymocytes (Morita & Munck, 1964; Makman et al., 1971; Hallahan et al., 1973) and murine peritoneal macrophages (Norton & Munck, 1980) . The conventional theory used to explain these findings is that glucocorticoids selectively decrease the number of glucose transporters in the plasma membrane (Carter-Su & Okamoto, 1985) . However, recent evidence from work on rat thymocytes suggests that in this cell type at least, dexamethasone, a synthetic glucocorticoid, inhibits 2-D-deoxyglucose (2-dGlc) uptake in a way that is consistent with decreased endofacial hexokinase activity in the vicinity of the glucose transporter . The object of the present study is to investigate if the inhibition of 2-dGlc uptake by dexamethasone in rat peritoneal macrophages can also be explained by decreased hexokinase activity.
In addition to their effects on sugar transport, glucocorticoids are known to modulate certain monocyte and macrophage functions (Guyre & Munck, 1987) . For example, glucocorticoids inhibit the tumoricidal activity of murine macrophages (Hogan & Vogel, 1988) and the anti-microbial activity of human macrophages (Schaffner, 1985) , and these effects may, at least in part, be due to a corticosteroid-induced suppression of superoxide production (Schultz et al., 1985; Maridonneau-Parini et al., 1989) . Superoxide production by phagocytes is associated with a rapid increase in metabolism known as the 'respiratory burst', and one of the characteristics of this process is increased hexose monophosphate shunt (HMPS) activity (Arthur et al., 1986 (Arthur et al., , 1988 , which produces NADPH. NADPH is the substrate required by NADPH oxidase for the production of superoxide, and thus inhibition of the activity of the HMPS will lead to suppressed free-radical generation. In this paper, we used phorbol myristate acetate (PMA)-induced HMPS activity as an indicator of superoxide production in order to investigate the ability of dexamethasone to inhibit these processes. RU 38486 is a steroid which has been shown to antagonize many of the effects of dexamethasone in vivo and in vitro, without marked agonist activity (Philibert, 1984) . It has been suggested that RU 38486 inhibits glucocorticoid effects by binding to the cytosolic glucocorticoid receptor, thus impairing its activation (Moguilewsky & Philibert, 1984) . However, the effect of RU 38486 on the dexamethasone-induced inhibition of 2-dGlc uptake in rat peritoneal macrophages has not previously been reported.
MATERIALS AND METHODS

Cell preparation
Rat peritoneal macrophages were prepared by the method described previously for 5-10 min, the cell suspension was then drawn out and centrifuged (300 g for 3 min), before being washed twice with saline. The average yield from one animal was approx. (1-2) x 107 macrophages, and each experiment required three or four rats.
Microscopy and cell counting
Optical microscopy of the cell preparation showed intact cells, with little debris, and 95 % of the cells excluded Evan's Blue stain. Differential counts of stained peritoneal washings showed > 90 % macrophages and monocytes.
Estimation of the mean cell volume of the macrophages was performed by measurement of the 3-O-methyl-D-glucose (3-OMG) space and confirmed by using an Elzone 280PC particle analyser (Particle Data Ltd., Kingstone, Hereford, U.K.). Macrophage volume was estimated as 330 fl, and all sugar uptake rates (etc.) are normalized to 3 x 109 cells or -1 ml of cell water. The Elzone 280PC analyser used to measure cell numbers, and macrophage suspensions were diluted to between 5 x I05 and 1 x 106 cells/ml.
Radioactive-sugar studies
Sugar uptakes into macrophages were performed using 2-deoxy-D-[2,6-3H]glucose or 2-deoxy-D-[l-3H)-glucose, (Amersham International; initial sp. radioactivity 42.5 Ci/mmol or 9 Ci/mmol respectively; final concn. approx. 0.5 ,uCi/ml), with or without dexamethasone (Sigma) or RU 38486 (Roussel Labs). Sugar uptake and exit was stopped by adding iso-osmotic ice-cold saline containing phloretin and HgCl2 at final concentrations of 100 /tM and ItM respectively. Uptake in the presence of this 'stopping solution' gives the background passive uptake of sugar, and all uptake rates are expressed as phloretinsensitive uptakes. After adding stopping solution, the cells were washed twice by centrifugation (for 3 min at 3000 g) and resuspension in fresh ice-cold stopping solution to remove extracellular isotope (a sample of the supernatant being retained for the determination of the extracellular radioactivity). Finally, the cells were lysed by vortex-mixing in distilled water, the lysate used to determine total uptake and, when required, free sugar and hexose phosphate concentrations within the cell pellet. Radioactivity was counted using scintillation fluid of the following composition: 1 litre of toluene (BDH), 1 litre of Synperonic NX (Durham Chemicals Distributors Ltd., Birtley, Tyne and Wear, U.K.) and 5 g of 2,5-diphenyloxazole (Sigma).
Estimation of phosphorylated and non-phosphorylated sugar Separation of phosphorylated and non-phosporylated sugar was performed by anion-exchange chromatography as previously described (Naftalin & Rist, 1989) . Briefly, a sample of ice-cold cell lysate was filtered through a Whatman DE81 anion-exchange filter in a Buchner filtration tube and the first filtrate, containing free sugar, was sampled. The sugar phosphate retained on the filter was washed off with 0.5 M-HC1 and also sampled. Both samples were then counted for radioactivity, and the amount of free sugar and hexose phosphate per 3 x 109 cells was estimated after correction for quench and dilution.
Radioactive sugar exit from preloaded cell suspensions
Freshly isolated macrophages were incubated with 2-d[1-3H]Glc (0.1 mM) for 4 h at 37°C, with or without dexamethasone (1 tM). The macrophages were then centrifuged at 1000 g for 3 min, the supernatants removed and the cells washed in saline at 20°C, before being re-centrifuged and finally resuspended in fresh saline with nominally zero sugar at 37 OC (2-dGlc < 0.005 mM).
Zero-trans net exit of total sugar was measured by observing the time-dependent loss of radioactivity from the cells into the nominally sugar-free solutions.
Determination of HMPS activity
Macrophages have an active HMPS pathway (Newsholme et al., 1986 (Newsholme et al., , 1987 that metabolizes 2-dGlc-6-phosphate via glucose-6-phosphate dehydrogenase and in the process cleaves the C-1 carbon atom from the sugar molecule. It follows that 3H label on the C-I carbon of 2-dGlc is lost from the cell as 3H20, whereas label at other positions will remain in the cytosol. Thus, by measuring the differential uptake of isotopes labelled at different positions, it is possible to determine the activity of the HMPS under various conditions.
RESULTS
Concentrations-dependent effects of dexamethasone and RU 38486 on 2-d12,6-3HIGlc uptake into macrophages Fig. 1 shows the concentration-dependence for dexamethasone on 2-d[2,6-3H]Glc (0.1 mM) uptake with or without RU 38486 (1 tM). Dexamethasone significantly decreased the uptake of 2-d[2,6-3H]Glc (0.1 mM) at all concentrations of glucocorticoid, (P < 0.001; in all cases n = 6) and the effect was concentrationdependent. The presence of RU 38486 (1 ,sM) during the preincubation significantly increased the uptake of 2-d[2,6-3H]Glc (0.1 mM) at 0, 0.1 and 1 uM-dexamethasone (P < 0.05, P < 0.001 and P < 0.01 respectively; n = 6), but did not have a significant effect at 10 uM-dexamethasone. Fig. 2 shows the concentration-dependence for RU 38486 on 2-d[2,6-3H]Glc (0.1 mM) uptake in the presence or absence of dexamethasone (0.1 /tM). RU 38486 caused a small, but significant, increase in sugar uptake at 0.01, 0.1 and 1 tM (P < 0.05, P < 0.01 and P < 0.05 respectively; n = 6). With dexamethasone (0.1 4uM) present the uptake of 2-dGlc was significantly decreased at 0, 0.01 and 0.1 ,tM-RU 38486 (P < 0.001, in all cases; n = 6), but not at 1 /tM-RU 38486.
These data indicate that dexamethasone causes a concentration-dependent inhibition of 2-dGlc uptake in native rat peritoneal macrophages, and RU 38486 competitively 15 min period. Dexamethasone significantly decreased the uptake of 2-dGlc at all concentrations (P < 0.001, in all cases; n = 6), and RU 38486 significantly increased uptake at 0, 0.1 and 1 /LM (P < 0.05, P < 0.001 and P < 0.01 respectively; n = 6), but not at 10 tMdexamethasone. O, Control; *, RU 38486 (1 ,M). There was no significant effect of preincubation in the control cells, but dexamethasone caused a significant time-dependent decrease in the uptake of 2-dGlc, (P < 0.001, at all times; n = 6). E, Control; *, dexamethasone (0.1 pM).
antagonizes this effect. By contrast, RU 38486 alone has a small stimulatory effect on the uptake of 2-dGlc, this may result from inhibition of the effects of endogenous glucocorticoids.
Time-dependent effects of dexamethasone (0.1 FM) on 2-dGIc uptake Fig. 3 shows that dexamethasone (0.1 gM) significantly decreased the uptake of 2-d[2,6-3H]Glc (0.1 mM) at 2, 4 and 6 h when compared with control (P < 0.001, in all cases; n = 6), and the inhibition of 2-dGlc uptake progressively increased as the preincubation time was increased. A 2 h preincubation with dexamethasone (0.1 M) inhibited 2-dGlc uptake by approx. 25 %, but after 6 h the inhibition was > 3g%.
A time-dependent inhibition of 2-dGlc uptake by dexamethasone has been reported in human fibroblasts (Homer et al., 1987) .
Vol. 278 and the free and phosphorylated sugars were separated by anionexchange chromatography (see the Materials and methods section). In control macrophages there was a 22-fold higher concentration of free 2-dGlc in the cytosol (2.20 + 0.09 mm; n = 8), than in the external saline (0.1 mM; Table 1 ). This free-sugar accumulation was significantly decreased by dexamethasone (100 nM) to 19-fold (1.94+0.06 mM; n = 6; P < 0.05). RU 38486
(1 gM) alone did not significantly alter the accumulation of free 2-dGlc (2.26 + 0.06 mM, n = 8), but in combination with dexamethasone (100 nM) it reversed the inhibitory effect of the glucocorticoid such that free 2-dGlc accumulation was not significantly different from the control value (2.36 + 0.13 mm, n = 7).
Effects of dexamethasone and RU 38486 on the zero-trans influx kinetics of 2-d12,6_3HJGIc uptake Total uptake of 2-d[2,6-3H]Glc was measured for 10 min at 37°C over a range of concentrations of the sugar (0.01-10 mM) after preincubation for 2 or 4 h in the presence or absence of dexamethasone (0-1 ,tM) and RU 38486 (1 ,tM). The data obtained after a 2 h incubation with 1 ,sM-dexamethasone were plotted by non-linear least-squares regression using the ENZFITTER program of the Michaelis-Menten equation (Fig.   4, main diagram) cells'1 (n = 8). Dexamethasone (1 /lM) significantly increased the Km (1.71 + 0.14 mM; P < 0.001), but did not significantly alter the Vm.a (1.53+0.11 #mol min-' 3 x 109 cells-'; n = 6). The inset shows a Lineweaver-Burk plot of the data, with the lines for control and dexamethasone both intersecting on the y-axis. This result indicates that dexamethasone is a competitive inhibitor of the zero-trans uptake of 2-d[2,6-3H]Glc. rO, Control; *, dexamethasone (1 ,M). respectively, and these were not significantly different from the K1 for 1 /tM. In contrast, preincubation for 4 h with 0.1 /Mdexamethasone significantly decreased the Ki for dexamethasonedependent inhibition of zero-trans 2-dGlc uptake to 0.10 + 0.06 /SM (P < 0.001; n = 5), indicating that there is a timedependent increase in the apparent affinity of agonist for the glucocorticoid-receptor-dependent inhibition of 2-dGlc uptake.
The calculated K, for RU 38486 (1 UM) on the reversal of 2-dGlc uptake inhibition by a 4 h incubation with dexamethasone (1 /sM) was 0.04+0.01 UM.
The data were also plotted as a Lineweaver-Burk plot (Fig. 4,  inset) , and this plot shows that the lines for control and dexamethasone intersect the y-axis at the same point, indicating that dexamethasone inhibits the uptake of 2-d[2,6-3H]Glc competitively.
Effects of dexamethasone (1 pM) on the zero-trans net exit of
2-dlj-3HlGlc
The exit of sugar from macrophages preloaded for 4 h with 2-d[1-3H]Glc (0.1 mM) in the presence or absence of dexamethasone (1 ,lM) was monitored by measuring the loss of radioactivity from the cells in nominally sugar-free medium (see the Materials and methods section). The decrease in total sugar is expressed as the percentage loss of radioactivity, with the zerotime value as the 100 % reference value. Fig. 5 shows that dexamethasone (1 #sM) significantly increased the rate of 2-d[1-3H]Glc (0.1 mM) exit from macrophages. The gradient for exit increased from -0.011 + 0.001 min-' (control, n = 5) to -0.015 + 0.001 min-' (n = 5; P < 0.05). Dexamethasone was reported to have the same effect on rat thymocytes ).
Effects of dexamethasone (0.1 pM) and RU 38486 (1 mM) on infinite-trans exchange uptake of 2-dGlc Freshly isolated macrophages were incubated at 37°C for 4 h with or without 40 mM-3-O-methyl-D-glucose (3-OMG), dexamethasone (0.1 IsM) and RU 38486 (1 uM). The cells were then centrifuged, washed with ice-cold saline to remove extracellular 3-OMG and immediately the uptake of 2-d[2,6-3H]Glc (0.1 mM) was measured over a 5 min period at 37°C (Table 2) . Pre-loading with 3-OMG (40 mM) significantly increased the uptake of 2-d[(2,6-3H]Glc (0.1 mM) in all the conditions when compared with zero-trans uptake (P < 0.001, in all cases; n = 6), but there is no significant difference between the maximal rates of exchange uptake of 2-dGlc. Since dexamethasone (0.1 aM) significantly decreased zero-trans uptake of 2-dGlc (P < 0.01; n = 6), it follows that the exchange component of 2-dGlc uptake into dexamethasone-treated cells pre-loaded with 3-OMG (40 mM) was increased. RU 38486 (1 4UM) alone did not significantly affect the zero-trans uptake of 2-d[2,6-3H]Glc (0.1 mM), but when present with dexamethasone it reversed the inhibitory effect of the glucocorticoid, such that zero-trans uptake was not significantly different from the control value. These findings are consistent with the view that dexamethasone reduces the coupling of hexokinase to 2-dGlc transport activity without changing the number of glucose transporters in the plasma membrane and that RU 38486 antagonizes these effects.
Effects of dexamethasone and RU 38486 on PMA-induced HMPS activity
Freshly isolated macrophages were incubated at 37°C for 4 h with various concentrations of dexamethasone (0- Table 2 . Effects of dexamethasone (Dexa) (0.1 jaM) and RU 38486 (1 sm) on the infinite-trans exchange uptake of 2-d [2, Macrophages were preloaded with or without 3-OMG (40 mM) for 4 h at 37°C in the presence or absence of dexamethasone (0.1 JM) and RU 38486 (1 #M). The cells were then washed with ice-cold saline (to remove the external sugar) and the uptake of 2-d[2,6-3H]Glc (0.1 mM) was measured over a 5 min period. Dexamethasone (0.1 pM) significantly decreased the zero-trans uptake of 2-dGlc (P < 0.01, n = 6), but RU 38486
(1 M) alone did not significantly alter the uptake of 2-dGlc (n = 6). The zero-trans uptake of 2-dGlc with RU 38486 and dexamethasone was not significantly different from the control (n = 6). In all conditions, preloading with 3-OMG (40 mM) (infinite-trans exchange uptake) significantly increased the uptake of 2-d[2,6-3H]Glc (0.1 mM) when compared with zero-trans uptake (P < 0.001, in all cases; n = 6). t P < 0.01; "., not significant (test versus control zero-trans uptake); *** P < 0.001 (test versus zero-trans uptake).
2-dGlc uptake (1umol 5 min-' ml of cell water'1) activity (umol 15 min-1 3 x 10 cells-1) was calculated from the difference in uptake of the labels and expressed as a percentage of the value in the absence of dexamethasone. All concentrations of dexamethasone significantly decreased PMA-induced HMPS activity (P < 0.01, in all cases; n = 6) and the effect was concentrationdependent. At 0.1 and 1, but not 10 /M-dexamethasone, RU 38486
(1 /M) significantly increased the HMPS activity compared with dexamethasone alone (P < 0.01, in both cases; n = 6). El, Control; *, RU 38486 (IuM). without RU 38486 (1 /SM). The activity of the HMPS was then determined by measuring the uptake of 2-d[l-3H]Glc and 2-d[2,6-3H]Glc (0.1 mM) for 15 min in parallel experiments in the presence of PMA (40 nM), a potent activator of the HMPS in rat peritoneal macrophages . The difference between the uptake of the two labels of 2-dGlc in ,umol * 15 min-1 * 3 x 109 cells-1 is equivalent to the amount of sugar metabolized by the HMPS pathway. Fig. 6 . shows a plot of the data with HMPS activity expressed as a percentage of the control value, i.e. in the absence of dexamethasone. Dexamethasone significantly decreased the PMA-induced HMPS activity at all concentrations of the glucocorticoid (P < 0.01, in all cases; n = 6), with uptake of 0.1 mM-2-dGlc inhibited by 60% at 1O /LM-dexamethasone. The presence of RU 38486 (1 /SM) with dexamethasone reversed the inhibitory effects of the glucocorticoid on PMA-induced HMPS activity. At 0.1 and 1 /SM-dexamethasone, RU 38486 (1 /zM) significantly increased HMPS activity above that with dexamethasone alone (P < 0.01, in both cases; n = 6). However, (Basketter & Widdas, 1978; Deves & Krupka, 1978) , and this correlates with the results presented here, since binding of inhibitor to the sugar transporter will inhibit both 2-d[2,6-3H]Glc uptake and HMPS activity.
Dexamethasone is shown to differentially inhibit HMPS activity and 2-d[2,6-3H]Glc uptake with increasing inhibition of 2-d[2,6-3H]Glc uptake (Fig. 7) . This finding indicates that dexamethasone may inhibit sugar uptake and HMPS activity, not only be decreasing the coupling between hexokinase and the sugar transporter (as reported above), but also at one or more additional points between the transporter and the HMPS pathway.
DISCUSSION
The results indicate, as previously reported for rat thymocytes , that dexamethasone decreases 2-dGlc uptake and accumulation in rat peritoneal macrophages by reducing the activity of hexokinase at the endofacial surface of the glucose transporter. The evidence for this is as follows: (1) dexamethasone significantly increased the Km for zero-trans uptake of 2-dGlc, without significantly altering the Vmax. (Fig.   4.) ; (2) the rate of exit of 2-dGlc from cells preloaded with sugar was significantly increased by dexamethasone (Fig. 5) ; (3) the free-sugar accumulation within the cytosol of the cells was significantly decreased by dexamethasone (Table 1) . Furthermore, the absence of any effect of dexamethasone on the maximal rate of exchange uptake of 2-dGlc into cells loaded with 3-OMG (Table 2) indicates that dexamethasone reduces hexokinase trapping of 2-dGlc rather than the number of transporters present within the membrane.
It has been reported that dexamethasone inhibits glucose transport in rat adipocytes by decreasing the number of transporters in the plasma membrane (Carter-Su & Okamoto, 1985) . However, an alternative model has been proposed which can explain the inhibitory effects of glucocorticoids on sugar transport (Naftalin & Smith, 1987) . This model suggests a 'loose coupling' between sugar transport and hexokinase activity and envisages that sugar emerging at the endofacial surface of the transporter can either be released into the cytosol, or remain on the transporter and be returned to the exofacial surface in a 'futile cycle', or be phosphorylated by hexokinase at the endofacial surface and then released into the cytosol. The hexokinase reaction forms impermeant sugar phosphate, thus reducing the recycling of permeant sugar via futile cycles and so increasing the net rate of uptake of sugar. It follows that a glucocorticoiddependent reduction in hexokinase activity at the endofacial surface of the transporter would lead to a number of predictions. Firstly, there would be an increase in the Km for zero-trans uptake of sugar, due to increased binding of free sugar at the endofacial surface of the transporter. Secondly, the rate of exit of free sugar would increase, because reduced phosphorylation of cytosolic free sugar bound to the endofacial surface of the transporter would allow the sugar to escape from the cell. Thirdly, there would be decreased accumulation of free sugar within the cell compared with the control, due to the combination of the first two effects together with the action of sugar phosphatases.
The finding that the results reported here agree with all the Prolonged incubation in the presence of glucocorticosteroids leads to lymphocytolysis, and it has been suggested that this is due to induction of nucleolytic products via a receptor-mediated pathway (Compton & Cidlowski, 1987) . However, recent work indicates that nucleosomal DNA cleavage is due to activation of an endogenous endonuclease(s) and does not require expression of a new nuclease (Alnemri & Litwack, 1989) .
RU 38486 shows powerful anti-glucocorticoid activity in vivo and in vitro and is also a potent anti-progesterone (Philibert, 1984) . It has been suggested that this antagonist effect is related to strong binding to the cytosolic glucocorticoid receptor, forming a stable complex (Moguilewsky & Philibert, 1984) . The relative binding affinity of RU 38486 is three times higher than that of dexamethasone at 0°C in the rat thymus, and this agrees with our finding that the K, for RU 38486 on the dexamethasonedependent inhibition of 2-d[2,6-3H]Glc uptake in rat macrophages (0.04+0.01 ltM) is lower than the K1 for dexamethasone itself (0.10 + 0.06 /uM). It has been reported that RU 38486 has no agonist effects (Philibert, 1984) , but our results show that RU 38486 treatment leads to a small but significant increase in 2-dGlc uptake in some cases, but not others (Fig. 2 , but not Table 2 ). This may be due to the presence of inhibitory levels of endogenous glucocorticoids in some cell preparations which are blocked by RU 38486, thus increasing sugar uptake.
These results indicate that dexamethasone induces a glucocorticoid-receptor-mediated response which leads to a loosening between hexokinase activity and glucose-transport activity and also uncoupling of the HMPS with hexokinase. This suggests a dual site of dexamethasone-induced inhibition of superoxide production and a schematic representation of the interactions between dexamethasone, PMA and cytochalasin B, and the various metabolic processes in the rat macrophage are shown in Scheme 1. Also, the inhibitory effect of dexamethasone on sugar transport and HMPS activity can be overcome when the external sugar concentration is increased, indicating that the anti-inflammatory effect of glucocorticoids in reducing superoxide production may only occur in macrophages in conditions where glucose uptake is low, e.g. in an inflamed hypoxic joint.
